Pacific Edge Limited

Equities

PEB

NZPEBE0002S1

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.085 NZD -1.16% Intraday chart for Pacific Edge Limited -1.16% -27.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
New Zealand Shares Flat on Thursday; Pacific Edge's Chair to Retire MT
Pacific Edge's Chair to Retire; Shares Fall 3% MT
Pacific Edge Limited Announces Board Changes CI
New Zealand Shares Flat on Monday; Genesis Minerals Secures Financial Close for Lauriston Solar Farm MT
Pacific Edge's Test Volume Declines Nearly 8% in Fiscal Q3; Shares Fall 3% MT
New Zealand Shares End the Year Flat Following a Two-Day Rally; Me Today to Undertake Share Consolidation MT
New Zealand Shares Post Back-to-Back Gains on Rate Cut Hopes MT
New Zealand Shares Rise on Strong Trading in Services Sector MT
Pacific Edge Limited(NZSE:PEB) dropped from S&P/NZX 50 Index Gross CI
Pacific Edge Limited(NZSE:PEB) dropped from S&P/NZX 50 Index CI
New Zealand Shares Fall on Monday; SkyCity Resolves Auckland Parking Concession Dispute MT
Pacific Edge Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Transcript : Pacific Edge Limited, H1 2024 Earnings Call, Nov 23, 2023
Pacific Edge Plans Coordinated Response to US FDA Proposal to Regulate Lab-Developed Tests MT
Pacific Edge Limited(NZSE:PEB) dropped from S&P Global BMI Index CI
Transcript : Pacific Edge Limited - Shareholder/Analyst Call
Pacific Edge Celebrates Extension of Novitas LCD Stay MT
Pacific Edge Expects 'Substantial' Decline in Revenue After Coverage Ceases for Urine Test MT
Transcript : Pacific Edge Limited - Special Call
Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023 CI
Pacific Edge Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Transcript : Pacific Edge Limited, 2023 Earnings Call, May 25, 2023
BCAL Diagnostics Appoints Advisor MT
Pacific Edge Completes Software Integration of Diagnostic Test with Kaiser Permanente MT
Pacific Edge Limited Provides Update on Kaiser EMR Integration CI
Chart Pacific Edge Limited
More charts
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas, and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.085 NZD
Average target price
0.145 NZD
Spread / Average Target
+70.59%
Consensus

Quarterly revenue - Rate of surprise